Can a simple blood test spot who will die from H1N1?
NCT ID NCT03641690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measured levels of mannose-binding lectin (MBL), a protein involved in immune response, in 97 ICU patients with severe H1N1-related acute respiratory distress syndrome (ARDS). Researchers wanted to see if higher or lower MBL levels were linked to a higher risk of death. The goal was to find a simple blood test that could help doctors identify the sickest patients sooner.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify high-risk H1N1 patients earlier, potentially guiding more aggressive treatment.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks for a link between a blood marker and outcomes, so it cannot prove cause or lead directly to a new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
97 people
The number who actually took part.
- Started
-
Sep 2013
- Finished
-
Dec 2017
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Any patient according to the present invention, has self optimized by a medical report: sedation, curarization, protective ventilation and adapted PEEP, under and without treatment with BAL and blood samples on the dry tube and EDTA in its care can be included in our study. At the time of the diagnosis of ARDS, and during the aetiological assessment, one can highlight a blood sample, samples of tubes for the assays of the inflammation.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who developed moderate-to-severe ARDS defined by the presence of bilateral alveolar images, a PaO2 / FiO2 ratio \<200 mmHg and the absence of an obvious cardiac cause, with or without the need for mechanical respiratory support extracorporeal circulation or decarboxylation. * Patient benefiting from nitric oxide. * Patient requiring continuous curarization. Exclusion Criteria: * Chronic renal insufficiency dialysis. * Severe hepatic insufficiency. * Patient under guardianship or curatorship or deprived of liberty. * "light" ARDS
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for H1N1 influenza are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens-Picardie
Amiens, 80054, France